Search for: "Allergan Inc"
Results 81 - 100
of 384
Sort by Relevance
|
Sort by Date
27 Jul 2018, 6:00 am
Mylan Pharmaceuticals, Inc., 18-1638 (Fed. [read post]
27 Jul 2018, 6:00 am
Mylan Pharmaceuticals, Inc., 18-1638 (Fed. [read post]
25 Jul 2018, 12:47 pm
Mylan Pharmaceuticals Inc. et al., the U.S. [read post]
25 Jul 2018, 1:45 am
Enlarge / Mylan Inc. [read post]
23 Jul 2018, 2:38 pm
By Jason Rantanen Saint Regis Mohawk Tribe, Allergan, Inc. v. [read post]
23 Jul 2018, 12:05 pm
Procedure – Impact of Factual Stipulation: Allergan Sales, LLC v. [read post]
20 Jul 2018, 11:44 pm
The outcome:Mylan Pharmaceuticals, Inc., petitioned for interpartes review (“IPR”) of various patents owned by Allergan,Inc., relating to its dry eye treatment Restasis. [read post]
3 Jul 2018, 7:12 am
Allergan, Inc. [read post]
13 Jun 2018, 11:39 pm
The Sackler family has sole ownership of Purdue and holds the majority of the seats on Purdue Pharma Inc. [read post]
9 Mar 2018, 7:37 am
Getty Images (US), Inc., 2018 WL 1156011, No. 16-CV-1362 (S.D.N.Y. [read post]
26 Feb 2018, 7:24 am
” See Speedplay, Inc. v. [read post]
26 Feb 2018, 5:05 am
Vas-Cath, Inc. v. [read post]
24 Feb 2018, 10:12 am
” Speedplay, Inc. v.Bebop, Inc., 211 F.3d 1245, 1250 (Fed. [read post]
16 Feb 2018, 2:06 pm
Inc. [read post]
5 Jan 2018, 2:02 am
, Inc. vs Akash Arora & Anr. [78 (1999) DLT 285)]. [read post]
3 Jan 2018, 5:10 am
On the heels of the Ericsson decision, further briefing on the waiver issue was recently authorized in Mylan Pharmaceuticals Inc., et al. v. [read post]
26 Dec 2017, 5:00 am
Massey, Pyott (Allergan), and Westmoreland (a Seventh Circuit case involving Baxter International).The case is No. 12151-VCG. [read post]
19 Dec 2017, 9:59 pm
But today, an expanded panel of the Board, including Chief Judge David Ruschke, issued an order dismissing a sovereign immunity challenge by the State of Minnesota in Ericsson Inc. and Telefonaktiebolaget LM Ericsson v. [read post]
19 Dec 2017, 3:13 pm
Apple Inc. v. [read post]
1 Dec 2017, 11:35 am
Big pharma players such as Eli Lilly, Novo Nordisk and Allergan are committed to voluntary price restraints, while companies such as Novartis and Roche are in favor of value-based pricing. [read post]
